Table 4.
Association between postoperative complications and adjuvant therapy access
| Variable | Total [n = 317] |
No adjuvant therapy [n = 80] | Adjuvant therapy [n = 237] | p-Value |
|---|---|---|---|---|
| Length of stay [median (IQR)] | 10 (11) | 13 (28.0) | 9 (4.0) | < 0.001 |
| Any complication | 159 (50.2) | 55 (68.7) | 104 (43.9) | < 0.001 |
| Major complications (CD ≥3) | 42 (13.2) | 17 (40.5) | 25 (10.5) | 0.014 |
| Clinically-relevant POPFa | 49 (15.5) | 22 (27.5) | 27 (1.4) | < 0.001 |
| Postpancreatectomy hemorrhageb | 25 (7.9) | 7 (8.8) | 18 (7.6) | 0.740 |
| Chyle leaka | 9 (2.8) | 3 (3.7) | 6 (2.5) | 0.571 |
| Delayed gastric emptyingb | 29 (9.1) | 8 (10.0) | 14 (5.9) | 0.213 |
| Re-intervention | 24 (7.6) | 9 (11.3) | 15 (6.3) | 0.150 |
| Abdominal collections | 40 (12.6) | 17 (21.2) | 23 (9.7) | 0.007 |
| Surgical site infection | 18 (5.7) | 9 (11.3) | 9 (3.8) | 0.012 |
| Sepsis | 45 (14.2) | 22 (27.5) | 23 (9.7) | < 0.001 |
| Cardiopulmonary complicationsc | 55 (17.4) | 23 (28.7) | 32 (13.5) | 0.001 |
Bold values indicate statistically significant
Data are expressed as n (%) unless otherwise specified
IQR interquartile range, CD Clavien–Dindo34, POPF postoperative pancreatic fistula, ISGPF International Study Group of Pancreatic Fistula, ISGPS International Study Group for Pancreatic Surgery
aGraded according to the ISGPF31
bGraded according to the ISGPS32,33
cIncluding any cardiopulmonary event requiring treatment